Azitra, Inc. to Present at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference

Company Overview - Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology [3] - The company's lead program, ATR-12, targets Netherton syndrome, a rare chronic skin disease with no approved treatment options [3] - Azitra's additional clinical program, ATR-04, addresses EGFR inhibitor associated skin toxicity, with a Phase 1/2 clinical trial initiated [3] Clinical Development - ATR-12 is currently in a Phase 1b clinical trial for adults with Netherton syndrome [3] - ATR-04 has received Fast Track designation from the FDA for treating EGFRi associated rash, which affects approximately 150,000 people in the U.S. [3] - Azitra's programs are developed from a proprietary platform of engineered proteins and topical live biotherapeutic products, utilizing a microbial library of around 1,500 bacterial strains [3] Upcoming Events - Azitra will present at the Biotech Showcase 2026 in San Francisco from January 12-14, 2026 [1] - The presentation will include one-on-one meetings with registered investors and potential partners to discuss the company's clinical development strategy and recent achievements [2] - The event is scheduled for January 13, 2026, at 2:30 PM PT, with Travis Whitfill, the Chief Operating Officer, as the presenter [2]